Placement of Extracranial Stimulating Electrodes and Measurement of Cerebral Blood Flow and Intracranial Electrical Fields in Anesthetized Mice
June 2nd, 2023
We describe a protocol for assessing dose-response curves for extracranial stimulation in terms of brain electrical field measurements and a relevant biomarker-cerebral blood flow. Since this protocol involves invasive electrode placement into the brain, general anesthesia is needed, with spontaneous breathing preferred rather than controlled respirations.
The cerebral blood flow can be measured by the degree of saturation of oxy deoxy hemoglobin. This increase in saturation is reduced with aging and in Alzheimer's model. We're estimating the strength of electrical stimulation using both applied currents and the intracranial electrical field density.
The most recent developments include improving extracranial stimulation for application to animal models of Alzheimer's disease. Currently, multiple imaging technologies in animal models, including laser spectral imaging, dual photo microscopy, and the physiological recording are used. The challenge is understanding the mechanistic basis for changes in dynamic cerebral blood flow responses in models of Alzheimer's disease.
We found the deficits in responses to metabolic challenges in Alzheimer's models mice, and applying extra cranial stimulation improves these deficits. The advantage of our protocol is that a stimulation-based approach improves cerebral blood flow.
View the full transcript and gain access to thousands of scientific videos
Overview
This study describes a protocol for assessing dose-response curves for extracranial stimulation through brain electrical field measurements and cerebral blood flow as a biomarker. The investigation focuses on the mechanistic understanding of dynamic cerebral blood flow responses, particularly in Alzheimer’s disease models, utilizing various imaging technologies.
Key Study Components
Area of Science
- Neuroscience
- Electrophysiology
- Cerebral Hemodynamics
Background
- Cerebral blood flow can be assessed via oxy-deoxy hemoglobin saturation levels, which decline with aging and in Alzheimer’s models.
- The strength of electrical stimulation is estimated using applied currents and intracranial electrical field density.
- The study aims to enhance extracranial stimulation for Alzheimer’s disease research.
- It highlights multiple imaging techniques used to analyze stimulation effects in animal models.
Purpose of Study
- To improve understanding of cerebral blood flow dynamics in Alzheimer’s disease models.
- To evaluate the efficacy of extracranial stimulation in mitigating deficits in metabolic responses.
- To provide a detailed protocol for conducting invasive electrode placements under anesthesia.
Methods Used
- The study utilized in vivo and imaging technologies in animal models.
- It involved assessing cerebral blood flow changes in models of Alzheimer’s disease following stimulation.
- The protocol necessitated invasive procedures with electrodes placed in the brain.
- General anesthesia with spontaneous breathing was employed for animal welfare.
Main Results
- Deficits in dynamic cerebral blood flow responses to metabolic challenges were identified in Alzheimer’s model mice.
- Extracranial stimulation significantly improved these deficits.
- This protocol demonstrated enhancements in cerebral blood flow following targeted stimulation, showcasing its efficacy.
Conclusions
- The study validates a stimulation-based approach to enhance cerebral blood flow, particularly in the context of Alzheimer's disease.
- It underscores the potential for using extracranial stimulation in therapeutic strategies for neurodegenerative conditions.
- The findings contribute to understanding neuronal mechanisms involved in metabolic responses and plasticity in disease models.
Frequently Asked Questions
Executive Industry Relevance
Quantitative measurement of cerebral blood flow (CBF) and intracranial electrical fields in response to transcranial alternating current stimulation (tACS) enables mechanistic de-risking in neurovascular target validation. This protocol supports predictive confidence for early-stage discovery in neurodegenerative disease models, particularly Alzheimer's, by linking stimulation parameters to functional vascular outcomes. The approach informs portfolio decisions on neuromodulation strategies and translational biomarker development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of neurovascular coupling mechanisms in disease-relevant animal models.
- Supports functional target validation by correlating electrical field strength with CBF changes.
- Facilitates predictive confidence in neuromodulation as a therapeutic hypothesis.
Screening & Assay Development
- Prepares validated in vivo systems for quantitative assessment of stimulation effects.
- Standardizes measurement of CBF and electrical field dose-response relationships.
- Enables reproducible evaluation of stimulation parameters across age and disease states.
Translational & Preclinical Research
- Aligns CBF response thresholds with translational biomarker strategies for neurodegeneration.
- Supports continuity from mechanistic discovery to preclinical validation in Alzheimer's and stroke models.
- Provides risk-adjusted data for advancing neuromodulation candidates.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical research, enabling hypothesis testing and quantitative readouts for neuromodulation strategies.
- Discovery Biology: Quantifies neurovascular response to electrical stimulation for mechanistic de-risking.
- Screening: Delivers standardized, reproducible CBF and field strength measurements for assay readiness.
- Analytics: Provides dose-response curves and statistical outputs for cross-condition comparison.
- Translational Research: Bridges animal model findings to human-relevant biomarker thresholds.
- Enterprise Reuse: Establishes a reusable platform for evaluating neuromodulation across neurodegenerative models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in neurovascular target engagement and functional outcomes.
- Operational Value: Standardizes in vivo measurement protocols for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions for neuromodulation programs and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of neurovascular and neuromodulation assets.
Implementation Considerations
- Requires expertise in in vivo electrophysiology and neurovascular imaging.
- Demands access to laser Doppler or speckle imaging and intracranial recording infrastructure.
- Necessitates cross-team standardization of anesthesia and physiological monitoring protocols.
- Adaptation may be needed for different animal ages, disease models, and electrode designs.
- Field size and regional specificity may be limited by imaging and recording techniques.
